mevalonic acid has been researched along with Urinary Bladder Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, L; Deng, M; Kang, T; Liu, Z; Ma, Z; Tang, H; Wu, Y; Zheng, L; Zheng, X; Zhou, L | 1 |
| Greife, A; Hatina, J; Schulz, WA; Scott, SD; Steinhoff, C; Tukova, J | 1 |
| Cuthbert, JA; Lipsky, PE | 1 |
3 other study(ies) available for mevalonic acid and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; RNA, Guide, CRISPR-Cas Systems; Transcription Factors; Urinary Bladder Neoplasms | 2023 |
Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation.
Topics: Antibiotics, Antineoplastic; Biosynthetic Pathways; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitory Concentration 50; Mevalonic Acid; Simvastatin; Transcriptome; Urinary Bladder Neoplasms | 2015 |
Suppression of the proliferation of Ras-transformed cells by fluoromevalonate, an inhibitor of mevalonate metabolism.
Topics: Animals; Carboxy-Lyases; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; Cholesterol; DNA Replication; Genes, ras; Humans; Interleukin-3; Kinetics; Mevalonic Acid; Recombinant Proteins; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1995 |